Depigmenting topical therapy based on a synergistic combination of compounds targeting the key pathways involved in melasma pathophysiology
Experimental Dermatology · 2023
DOI: 10.1111/exd.14752 ↗At a glance
Journal article in Experimental Dermatology, 2023. Written by Martínez-Gutiérrez Alfredo and 5 co-authors. Institution: Biotechnology Unit, Mesoestetic Pharma Group, Barcelona, Spain. Major MEDLINE topics: Diosmin, Melanosis. Cited 10 times so far (Crossref); 50 references.
Abstract (original language)
Melasma has a complex pathophysiology with different cell types and signalling pathways involved. Paracrine factors secreted by keratinocytes, fibroblasts and endothelial cells act on melanocytes and stimulate melanogenesis. These paracrine factors are involved in the oxidative stress, inflammatory, vascular and hormonal pathways, among others. Damage of the dermoepidermal barrier also occurs and facilitates melanin deposition in the dermis, also known as dermal or mixed melasma. We used artificial intelligence tools to define the best combination of compounds for skin pigmentation inhibition. Mathematical models suggested the combination of retinol, diosmin and ferulic acid to be the most effective one. In vitro cellular tyrosinase activity assay proved that this combination had a synergistic depigmenting effect. Further assays proved that the combination could inhibit key pathways involved in melasma by downregulating ET‐1 and COX‐2 gene expression and IBMX‐induced dendricity in human melanocytes, and upregulated the gene expression of IL‐1b , TIMP3 and several endogenous antioxidant enzymes. The combination also reduced melanin levels in a phototype VI 3D epidermis model. These results indicate that the combination of retinol, diosmin and ferulic acid is an effective synergistic complex for the treatment of melasma by regulating the key molecular pathways involved in skin hyperpigmentation pathophysiology.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Biotechnology Unit, Mesoestetic Pharma Group, Barcelona, Spain.
- Medical Unit, Mesoestetic Pharma Group, Barcelona, Spain.
ORCID profiles: Martínez-Gutiérrez Alfredo
Cite
APA
Alfredo, M. G., Maribel, P. M., Eloy, P. R., Susana, G. E., Luis, L. G. S., & Carmen, G. M. (2023). Depigmenting topical therapy based on a synergistic combination of compounds targeting the key pathways involved in melasma pathophysiology. Experimental Dermatology. https://doi.org/10.1111/exd.14752
Vancouver
Alfredo MG, Maribel PM, Eloy PR, Susana GE, Luis LGS, Carmen GM. Depigmenting topical therapy based on a synergistic combination of compounds targeting the key pathways involved in melasma pathophysiology. Experimental Dermatology. 2023. doi:10.1111/exd.14752
BibTeX
@article{Alfredo2023,
author = {Alfredo, Martínez-Gutiérrez and Maribel, Pérez-Martínez and Eloy, Pena-Rodríguez and Susana, Gómez-Escalante and Luis, Luis G S and Carmen, González Mari},
title = {Depigmenting topical therapy based on a synergistic combination of compounds targeting the key pathways involved in melasma pathophysiology},
journal = {Experimental Dermatology},
year = {2023},
doi = {10.1111/exd.14752}
}
EUVIMED